



EDITORIAL

BENTHAM
SCIENCE

The Current Evidence for the Therapeutic Role of Curcumin in Alzheimer's Disease

Abigail R. Bland¹, John C. Ashton¹, Mohammad Amjad Kamal^{2,3,4,5} and Amirhossein Sahebkar^{6,7,8,9,*}

¹Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand; ²Institutes for Systems Genetics, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China; ³King Fahd Medical Research Center, King Abdulaziz University, P.O. Box 80216, Jeddah 21589, Saudi Arabia; ⁴Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka, Bangladesh; ⁵Enzymoics, Novel Global Community Educational Foundation, 7 Peterlee Place, Hebersham, NSW 2770, Sydney, Australia; ⁶Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; ⁷Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; ⁸School of Medicine, The University of Western Australia, Perth, Australia; ⁹School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

ARTICLE HISTORY

Received: August 09, 2021

Revised: November 25, 2021

Accepted: November 25, 2021

DOI:

10.2174/1871527321666220119105836



CrossMark

Keywords: Curcumin, Alzheimer's disease, A β , neurodegenerative disorder, β - and γ -secretases, Ca²⁺ channels.

Alzheimer's disease (AD) is a progressive neurodegenerative disorder, accounting for approximately 60-80% of all dementia cases, with an estimated 24 million patients worldwide [1]. The disease affects cognitive function, resulting in memory, language, and behavioral deficits and an inability to perform basic daily activities [1]. Although the exact mechanism surrounding the development of AD is not well understood, one major hypothesis is that neuronal loss is subsequent to neuroinflammation, following deposition of amyloid- β (A β) plaques and the generation of neurofibrillary tangles (which is a result of abnormal tau protein phosphorylation) [2]. A β plaques are created following the cleavage of amyloid precursor protein (APP) by β - and γ -secretases into insoluble A β peptides. The aggregates of A β have multiple neurotoxic mechanisms including binding to Ca²⁺ channels (which increases intracellular Ca²⁺ levels and induces excitotoxicity apoptosis), producing oxidative stress (*via* increasing levels of reactive oxygen species) and initiating the formation of neurofibrillary tangles (which produce neuronal death due to a communication disruption between neurons) [3]. Currently, the only approved drugs for the treatment of AD are used for symptomatic relief and do not prevent disease progression [4]. These drugs mainly inhibit the acetylcholinesterase enzyme, preventing the breakdown of acetylcholine at the synapse, and allowing more cholinergic neurotransmission. Another drug target is the NMDA receptor, which when antagonised, results in a decrease in the Ca²⁺ influx, thereby reducing excitotoxicity [4]. As the available drugs only aid in reducing the symptoms of the disease, treatments targeting the pathogenesis, and hence, preventing the progression of the disease, need to be explored. One route of investigation has focused on antibody treatments aimed at degrading A β plaques [5]. Another strategy involves the screening of known bioactive compounds in models of AD.

Curcumin is a bioactive phytochemical from turmeric and is thought to hold pleiotropic activities such as anti-inflammatory, anti-apoptotic and anti-oxidant effects [6-8]. It is currently being examined for the treatment of several diseases, including AD [9]. Curcumin has been reported to reduce neuroinflammation, oxidative stress and A β aggregation, preventing neurotoxicity in models of AD [9]. Of the mechanisms explored, the prevention of A β plaques is promising due to this being the major hypothesis in the development and progression of AD. Yang *et al.* (2005) reported that Tg2576 mice (a highly relevant mouse model with age-related cognitive deficits), aged 17 months, treated with 500 ppm of curcumin for 5 months had significant 32.5% and 85% reductions in the plaque burden and insoluble A β levels, respectively, compared to control mice [10]. It is thought that this effect is due to an inhibition of the β -amyloid precursor protein cleaving enzyme (BACE-1), which is the first enzyme involved in the cleavage of APP to A β . Using a *Drosophila melanogaster* model (which overexpressed BACE-1), Wang *et al.* (2014) demonstrated that demethoxycurcumin had a strong inhibition on BACE-1 with an IC₅₀ of 17 μ M [11]. Further analysis into this mechanism revealed that curcumin activates the Wnt/ β catenin pathway, which inhibits the transcription of BACE-1 *via* T-cell factor-4 [12]. Curcumin has also been shown to reduce oxidative stress in preclinical models of AD. Rats with streptozotocin-induced dementia and orally treated with curcumin (10, 20 or 50 mg/kg) for 21 days had a dose-dependent reduction in the

*Address correspondence to this author at the School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran; E-mails: amir_saheb2000@yahoo.com; sahebkar@mums.ac.ir

levels of MDA (a marker of oxidative stress), which also correlated to a dose-dependent increase in GSH (free radical scavenger) within the brain [13]. Therefore, there is a large amount of preclinical evidence suggesting that curcumin may aid in preventing disease progression in AD.

Curcumin for use in AD has also been examined in clinical trials. However, results to date have been mixed. Cox *et al.* (2015) reported that a lipid formulation containing 80 mg of curcumin had a significant positive effect on memory and sustained attention in healthy adults aged 65-80 years [14]. Conflicting data were published by Baum *et al.* (2008), who found that both 1 and 2 g of curcumin, administered for 6 months, did not affect mini-mental state examination scores in adults aged over 50 with AD and cognitive decline. However, although not significant curcumin increased the serum A β levels, indicating that curcumin may prevent A β aggregation [15]. Small *et al.* (2018) also reported a significant reduction in amyloid and tau accumulation in the amygdala, with significant improvements in memory and attention being observed in healthy adults (aged between 51 and 84 years) with curcumin treatment (90 mg, twice daily for 18 months) [16]. Curcumin has also been shown to enhance A β clearance by macrophages in AD patients [17, 18]. Zhang L. *et al.* (2006) isolated macrophages from AD patients and reported that macrophages following curcumin treatment resulted in a significantly greater A β uptake and co-localisation of A β with the intracellular component, phalloidin, when compared to control macrophages [17]. The authors also demonstrated that macrophages isolated from AD patients had a significantly lower uptake of A β compared to macrophages isolated from healthy patients [14]. This effect was confirmed by Masoumi *et al.* (2009), who reported that curcuminoids provided additivity with 1 α ,25-dihydroxyvitamin D₃ and provided greater A β phagocytosis and clearance with macrophages from AD patients [18]. Although the clinical trial data is conflicting on if curcumin significantly improves cognitive decline, there is evidence that it can prevent A β aggregation and increase uptake and clearance. If curcumin can provide these effects in AD patients, this drug could prevent disease progression, something that is currently lacking with our current therapeutics. More clinical trials comparing early and late-stage AD patients are needed to confirm this effect and determine the therapeutic value of curcumin in AD. Finally, it remains to be clarified if any pharmacological effect of curcumin in improving cognitive deficits in AD could be augmented by utilising novel drug delivery systems, which have been recently shown to enhance the oral bioavailability of curcumin in humans.

CONFLICT OF INTEREST

Dr. Mohammad Amjad Kamal is the Regional Editor of the journal CNS & Neurological Disorders- Drug Targets (CNS & Neurological Disorders - Drug Targets).

ACKNOWLEDGEMENTS

Declared none.

REFERENCES

- [1] Erkinen MG, Kim MO, Geschwind MD. Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. *Cold Spring Harb Perspect Biol.* 2018; 10(4).
- [2] Du X, Wang X, Geng M. Alzheimer's disease hypothesis and related therapies. *Transl Neurodegener.* 2018; 7: 2.
- [3] Abeyasinghe A, Deshapriya R, Udawatte C. Alzheimer's disease; a review of the pathophysiological basis and therapeutic interventions. *Life Sci.* 2020; 256: 117996.
- [4] Mendiola-Precoma J, Berumen LC, Padilla K, Garcia-Alcocer G. Therapies for Prevention and Treatment of Alzheimer's Disease. *Biomed Res Int.* 2016; 2016: 2589276.
- [5] Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, *et al.* The antibody aducanumab reduces A β plaques in Alzheimer's disease. *Nature.* 2016; 537(7618): 50-6.
- [6] Shakeri A, Cicero AFG, Panahi Y, Mohajeri M, Sahebkar A. Curcumin: A naturally occurring autophagy modulator. *J Cell Physiol.* 2019 May;234(5):5643-5654. doi: 10.1002/jcp.27404. Epub 2018 Sep 21. PMID: 30239005.
- [7] Afshari AR, Jalili-Nik M, Abbasinezhad-Moud F, Javid H, Karimi M, Mollazadeh H, Jamialahmadi T, Sathyapalan T, Sahebkar A. Anti-tumor Effects of Curcuminoids in Glioblastoma Multiforme: An Updated Literature Review. *Curr Med Chem.* 2021; 28(39): 8116-8138. doi: 10.2174/0929867327666201111145212. PMID: 33176632.
- [8] Mortezaee K, Salehi E, Mirtavoos-Mahyari H, Motevaseli E, Najafi M, Farhood B, Rosengren RJ, Sahebkar A. Mechanisms of apoptosis modulation by curcumin: Implications for cancer therapy. *J Cell Physiol* 2019; 234(8): 12537-12550. doi: 10.1002/jcp.28122. PMID: 30623450.
- [9] Voulgaropoulou SD, van Amelsvoort T, Prickaerts J, Vingerhoets C. The effect of curcumin on cognition in Alzheimer's disease and healthy aging: A systematic review of pre-clinical and clinical studies. *Brain Res.* 2019; 1725: 146476.
- [10] Yang F, Lim GP, Begum AN, *et al.* Curcumin inhibits the formation of amyloid-beta oligomers and fibrils, binds plaques, and reduces amyloid *in vivo*. *J Biol Chem.* 2005; 280(7): 5892-901.
- [11] Wang X, Kim JR, Lee SB, *et al.* Effects of curcuminoids identified in rhizomes of *Curcuma longa* on BACE-1 inhibitory and behavioral activity and lifespan of Alzheimer's disease *Drosophila* models. *BMC Complement Altern Med.* 2014; 14: 88.
- [12] Parr C, Mirzaei N, Christian M, Sastre M. Activation of the Wnt/ β -catenin pathway represses the transcription of the β -amyloid precursor protein cleaving enzyme (BACE1) *via* binding of T-cell factor-4 to BACE1 promoter. *FASEB J.* 2015; 29(2): 623-35.
- [13] Awasthi H, Tota S, Hanif K, Nath C, Shukla R. Protective effect of curcumin against intracerebral streptozotocin induced impairment in memory and cerebral blood flow. *Life Sci.* 2010; 86(3-4): 87-94.
- [14] Cox KH, Pipingas A, Scholey AB. Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population. *J Psychopharmacol.* 2015; 29(5): 642-51.

- [15] Baum L, Lam CW, Cheung SK, *et al.* Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. *J Clin Psychopharmacol.* 2008; 28(1): 110-3.
- [16] Small GW, Siddarth P, Li Z, *et al.* Memory and Brain Amyloid and Tau Effects of a Bioavailable Form of Curcumin in Non-Demented Adults: A Double-Blind, Placebo-Controlled 18-Month Trial. *Am J Geriatr Psychiatry.* 2018; 26(3): 266-77.
- [17] Zhang L, Fiala M, Cashman J, *et al.* Curcuminoids enhance amyloid-beta uptake by macrophages of Alzheimer's disease patients. *J Alzheimers Dis.* 2006; 10(1): 1-7.
- [18] Masoumi A, Goldenson B, Ghirmai S, *et al.* 1alpha,25-dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of Alzheimer's disease patients. *J Alzheimers Dis.* 2009; 17(3): 703-17.